Eslicarbazepine acetate

Eslicarbazepine acetate

Systematic (IUPAC) name
(S)-10-Acetoxy- 10,11-dihydro- 5H-dibenz[b,f]azepine- 5-carboxamide
Clinical data
Pregnancy category	C
Legal status	US: ℞-only ℞ (Prescription only)
Routes of administration	Oral
Pharmacokinetic data
Excretion	~90% renal
Identifiers
CAS Number	236395-14-5
ATC code	N03AF04
PubChem	CID 179344
ChemSpider	156110
ChEMBL	CHEMBL1067
Chemical data
Formula	C17H16N2O3
Molar mass	296.320 g/mol
SMILES CC(=O)OC2Cc1ccccc1N(C(N)=O)c3c2cccc3
InChI InChI=1S/C17H16N2O3/c1-11(20)22-16-10-12-6-2-4-8-14(12)19(17(18)21)15-9-5-3-7-13(15)16/h2-9,16H,10H2,1H3,(H2,18,21)/t16-/m0/s1 Key:QIALRBLEEWJACW-INIZCTEOSA-N

Eslicarbazepine acetate (brand names Aptiom, Zebinix, Exalief), abbreviated as ESL, is an anticonvulsant medication approved for use in Europe and the United States as an adjunctive therapy for epilepsy.^[1][2]

Similarly to oxcarbazepine, ESL behaves as a prodrug to eslicarbazepine ((S)-(+)-licarbazepine).^[3] As such, their mechanisms of action are identical.^[4] However, there may be pharmacokinetic differences between the two drugs; for instance, ESL may not produce as high of peak levels of (S)-(+)-licarbazepine immediately after dosing as does oxcarbazepine, which could, in theory, improve tolerability.

Like oxcarbazepine, ESL may be used to treat bipolar disorder and trigeminal neuralgia.

See also

• Carbamazepine

References

1. "Press Announcements > FDA approves Aptiom to treat seizures in adults".
2. "European Medicines Agency - Find Medicine - Zebinix".
3. Rogawski MA (June 2006). "Diverse mechanisms of antiepileptic drugs in the development pipeline". Epilepsy Res. 69 (3): 273–94. doi:10.1016/j.eplepsyres.2006.02.004. PMC 1562526. PMID 16621450.
4. Rogawski MA, Löscher W (July 2004). "The neurobiology of antiepileptic drugs". Nat. Rev. Neurosci. 5 (7): 553–64. doi:10.1038/nrn1430. PMID 15208697.